Preimplantation Genetic Diagnosis Market Key Players – Amgen, Quest Diagnostics, Genentech Inc., Vertex, PerkinElmer, Inc., F. Hoffman-La-Roche Ltd Etc. – Analysis and Forecast to 2027
Preimplantation genetic diagnosis (PGD) is a procedure used before implantation to help identify genetic defects within embryos. This helps in preventing certain genetic diseases or disorders from being passed on to the child. Generally, the embryos used in PGD are created during the process of in vitro fertilization (IVF). PGD is also beneficial in avoiding selective pregnancy termination by the development and growth of the healthy fetus. Moreover, it serves as an addendum to assisted reproductive technology. In layman’s terms, the preimplantation genetic diagnosis is a technique that is used to identify embryos at risk.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-sample/698
This process is comprised of DNA analysis, in order to figure out mutations or previous records of genetic or chromosomal disorders in the family, with the help of a procedure known as preimplantation genetic profiling.
Market Dynamics- Drivers
Growing rates in birth defects creating opportunities for expansion of the global preimplantation genetic diagnosis market
Increasing rates of birth defects worldwide is expected to drive growth of the global preimplantation genetic diagnosis market during the forecast period. According to the World Health Organization (WHO) and March of Dimes (MOD) joint report, in 2013, the prevalence of birth defects in India is 61 to 70 per 1,000 live births. According to the same source, around 70% of these birth defects are preventable offering lucrative opportunities for growth the global preimplantation genetic diagnosis market. A scientific report in the Nature journal states that 7.9 million infants accounting up to 6% of the worldwide births are born with serious birth defects, out of which over 50% of defects are unknown. These defects may be due to chromosomal abnormalities that could be investigated using preimplantation genetic diagnosis preventing defective births and propelling the global market.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/698
On the basis of tests type, the chromosomal abnormality segment witnessed a huge adoption in the global preimplantation genetic diagnosis market. This is owing to rise in hereditary, genetic, and chromosomal diseases.
Market Dynamics- Restraints
However, strict government policies leading restriction of gender selection is expected to restrain growth of the global preimplantation genetic diagnosis market over the forecast period.
Increasing awareness among the population regarding the prevention of genetic diseases and reproduction health propelling the global preimplantation genetic diagnosis market growth
Increasing awareness among people to undergo diagnostic tests, in order to prevent birth defects is expected to drive growth of the global preimplantation genetic diagnosis market in the near future. According to the National Institutes of Health (NIH), which aims for biomedical and public health research, around 50% of children are affected by rare diseases. These diseases may include chromosomal defects as well as hereditary disorders.
Moreover, high demand from people seeking in vitro fertilization treatments and advancements in the PGF availing diagnosis of diseases such as cancer and minor disabilities such as deafness are expected to drive the market growth.
Global Preimplantation Genetic Diagnosis Market- Regional analysis
Based on the geographical segmentation, the global preimplantation genetic diagnosis market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Among regions, Europe holds the dominant position in the global preimplantation genetic diagnosis market, owing to increasing number of late pregnancies, which are mostly expected to be IVFs. Furthermore, liberties in the regulations of various countries in Europe have added potential avenues to employ aneuploidy screening thereby making it the top shareholder of the global preimplantation genetic diagnosis market.
Moreover, Asia Pacific is expected to witness the fastest growth during the forecast period, owing to advancements in reproductive healthcare facilities and rising revenue generation. Chinese regulatory bodies volunteering to monitor reproductive challenges in the country and encourage the adoption of services to solve the challenges may propel the market growth in China.
Global Preimplantation Genetic Diagnosis Market- Competitive Landscape
Major companies operating the global preimplantation genetic diagnosis market include Abbott Laboratories, Illumina, Inc., Natera Inc., PerkinElmer, Inc., F. Hoffman-La-Roche Ltd, Thermo Fisher Scientific, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics, Inc., Reproductive Genetics Institute and Genea Ltd. These players are consistently involved in enhancing the efficiency of the diagnosis process providing better healthcare solutions to the global population.
In December 2018, Agilent Technologies Inc., introduced OnePGT, a genome-wide, next-generation sequencing (NGS) solution for preimplantation genetic testing (PGT).
In October 2018, Illumina Inc. signed an agreement with Vitrolife AB under which Vitrolife act as a distributor supplier of Illumina’s PGT products in EMEA and America.
In August 2017, Invitae Corporation, acquired privately-held Good Start Genetics, a molecular diagnostics company, and CombiMatrix a company that specializes in prenatal diagnosis. This acquisition will establish Invitae Corporation as a comprehensive provider of genetic information.
In April 2016, CombiMatrix Corporation, launched CombiPGD – Preimplantation Genetic Diagnosis (PGD) for single gene disorders and chromosomal translocations.
In 2015, Natera Inc. entered into a partnership with MedGenome, a provider of genomic solutions for personalized healthcare in India. As per this partnership, MedGenome will be allowed to use the Panorama noninvasive prenatal test in its research laboratory
To understand Research Methodology, please click https://www.coherentmarketinsights.com/market-insight/preimplantation-genetic-diagnosis-market-698
Global Preimplantation Genetic Diagnosis Market- Taxonomy
The global preimplantation genetic diagnosis market is segmented on the basis of test types and geographical regions.
By Test types
- Chromosomal Abnormalities
- Gender Selection
- X- Linked Diseases
- Single Gene Disorders
- North America
- Latin America
- Asia Pacific
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire